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Abstract: 
Introduction: Acute viral respiratory illnesses are associated with acquisition of 
Pseudomonas aeruginosa infection in Cystic Fibrosis (CF) patients.  
Objectives: To pilot a protocol for a randomised controlled trial to determine whether 
oral anti-pseudomonal antibiotics used at the onset of such episodes might delay 
onset of infection with this organism. 
Methods: Forty-one children with CF aged 2-14 years, without chronic 
Pseudomonas infection, were randomised to receive ciprofloxacin (n=28) or placebo 
(n=13) at the onset of acute viral respiratory infections on an intention to treat basis, 
during a study period of up to 32 months. 
Results and Conclusions: There were no unexpected adverse events believed 
related to the use of the study medication.  The rate of withdrawal from the study 
was low (approximately 7%) and did not differ between groups. Randomisation was 
effective and acceptable to participants. Primary and secondary outcome measures 
all favoured active treatment but there were no significant between group 
differences.  The median rate of pseudomonas isolates was 0/patient/year, 
(interquartile range 0-0.38) in both the active and placebo groups.  Kaplan Meier 
survival curves showed no significant difference in time to first Pseudomonas isolate 
between groups.   
This study demonstrated the clinical feasibility of using oral ciprofloxacin in cystic 
fibrosis patients at times of viral infection.  Within this sample size no significant 
association was found between active treatment and decreased growth of 
Pseudomonas on follow-up microbiological samples.  A definitive study would 
require at least 320 children to demonstrate significant differences in the rate of 
pseudomonal isolates. 
UK NIHR PortfolioUK CRN study ID 7857 
EUDRACT Registration: 2008-001769-27 
Key words: Cystic Fibrosis, Pseudomonas aeruginosa, Ciprofloxacin, Randomised 
controlled trial 
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Ethical statement: UK NHS Ethics Approval was gained (08/H0504/110). The study 
was performed in accordance with the ethical standards laid down in the Declaration 
of Helsinki.  Parents of all participating children gave informed written consent and 
children aged over 11 years were asked to provide written assent. 
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Introduction: 
Cystic fibrosis (CF) disease-related morbidity and mortality are most commonly a 
result of progressive lung disease.  This is characterised by a self-perpetuating cycle 
of bacterial infection and airway inflammation [1].  Studies have characterised the 
involvement of a range of bacterial, viral and fungal species in the pathogenesis of 
CF lung disease, [2] but Pseudomonas aeruginosa remains the most common 
organism causing chronic endo-bronchial infection associated with deteriorating 
respiratory health.  Current concepts of care include the early use of anti-
pseudomonal antibiotics after the initial detection of P. aeruginosa in respiratory 
samples[3,4].  This approach has been successful in temporarily eradicating P. 
aeruginosa and thus delaying the onset of chronic infection, but eradication attempts 
typically become less successful over time and most patients eventually become 
chronically infected [5].  Preventive strategies using regular inhaled anti-
pseudomonal antibiotics [6] and routine bronchial lavage sampling to improve early 
identification and treatment of P. aeruginosa infection [7], have not been shown to be 
effective.  
 
Laboratory studies have characterised the synergistic role of viruses as co-infecting 
respiratory pathogens predisposing to the onset of infection with P. aeruginosa [8,9].  
In a prospective study of 38 children with CF, for 6 of the 7 children in whom P. 
aeruginosa was first isolated during the study period, first isolates of P. aeruginosa 
were identified during, or within 3 weeks of, a viral upper respiratory tract infection 
[10].  More recently, during one winter period, 6 of 20 prospectively studied children 
with CF (age range 0.1 to 7.4 years) had at least one P. aeruginosa positive culture 
from specimens collected at the time of acute viral respiratory infection [11].  Initial 
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onset of pseudomonal infections have been shown to have a seasonal pattern of 
occurrence temporally related to winter months when viral infections with pathogens 
such as RSV and influenza are more common [12-15]. 
 
These data suggest that individuals with CF might be at increased risk of infection 
with P. aeruginosa during episodes of viral respiratory tract infection but there are no 
randomised controlled trials of anti-pseudomonal prohylaxis during viral infections  
We investigated the feasibility of using a randomised controlled trial protocol to 
investigate the hypothesis that the oral anti-pseudomonal antibiotic ciprofloxacin, 
used at the onset of viral upper respiratory tract symptoms, can prevent the 
subsequent growth of P. aeruginosa from follow-up respiratory tract cultures.  
 
Patients and Methods: 
Following UK NHS Ethics Approval (08/H0504/110), all children aged 2-14 years 
with a confirmed diagnosis of CF and attending either the regional CF service for full 
care or shared care with one of two referral hospitals were screened for study 
inclusion.  Those with negative Pseudomonas ELISA serology and judged not to be 
chronically infected with P. aeruginosa [16] or any other gram negative organism, 
and who had not received regular anti-pseudomonal antibiotics in the previous 6 
months, were invited to participate.  Parents of all participating children gave 
informed written consent and children aged over 11 years were asked to provide 
written assent.  
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Children were randomised in blocks of 9 (6 active versus 3 placebo, see consort 
diagram figure 1).  Restricted randomisation was used with stratification by clinic in a 
double blind manner.  Participants received ciprofloxacin syrup or placebo treatment 
for viral infections for 32 months or until study end if this was sooner.  Very low rates 
of infective episodes were reported during late spring and summer months and for 
this reason the study was stopped earlier than had originally been planned and 
before all study participants had been followed up for 32 months. The first patient 
was recruited into the study in December 2009 and the last in January 2011, the 
study ended in March 2013.  Parents were instructed to contact the CF research 
nurses if their child experienced symptoms suggestive of acute viral respiratory 
illness including a runny nose, nasal congestion, sore throat and sneezing with or 
without fever.  Parents also received fortnightly reminder texts from the research 
nurse to make contact in the event of these symptoms.  When acute symptoms were 
reported, these were verified by the research team and arrangements made for the 
family to receive, according to randomisation group, a two week course of either 
ciprofloxacin syrup (Bayer plc; Dose according to the British National Formulary for 
Children 20mg/kg/day twice daily aged > 5years; 15mg/kg/day twice daily age 2-5 
years) or a placebo of the syrup suspension alone prepared by the clinical trial 
pharmacy at University Hospital Southampton NHS Foundation Trust.  If cough 
persisted for more than 48 hours, children were assessed and treated with additional 
oral antibiotics by the CF clinical team according to regional protocols.  
Microbiological specimens were obtained at out-patient clinic visits every two months 
and when clinically indicated.  Separate to the study procedures, all positive isolates 
of P. aeruginosa were treated according to local clinical guidelines with 3 months 
inhaled colomycin plus oral ciprofloxacin (3 weeks for first isolates and 3 months for 
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subsequent isolates) or a combination of two intravenous antibiotics.  Study 
medication was discontinued during these treatment periods.  Children who became 
chronically infected with P. aeruginosa were no longer eligible for inclusion within the 
trial. 
 
The pre-determined primary clinical outcome was the annual rate of positive isolates 
of P. aeruginosa.  Secondary outcome measures included time to first detection of P. 
aeruginosa, change in pseudomonal serology and annual rates of nebulised and 
intravenous antibiotic prescription.    
 
Statistical considerations: 
All data were analysed on an intention to treat basis. We aimed to recruit 45 children 
into the study and used a 2:1 asymmetrical study design favoring active treatment to 
maximise safety and efficacy data for the study intervention.  Based on published 
epidemiological studies [17], and review of PortCF data, we anticipated that P. 
aeruginosa would be detected in approximately one third of the control group.  The 
number of children becoming chronically infected, according to the definition of >50% 
of samples positive for Pseudomonas over 12 months, was anticipated to be 
small[16].  However, the overall isolation rate was judged to be a clinically significant 
outcome of direct relevance to chronic colonisation.  Given the absence of trial data 
relating to anti-pseudomonal prophylaxis during viral infaction, the likely size of any 
between group difference in overall isolation rate was unknown. This study was 
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designed to provide important safety and feasibility data for this treatment approach 
and to inform the design and sample size of further trials in this age group.  
 
Many of the outcomes were positively skewed so non-parametric tests were used for 
between group comparisons.  Bonferroni correction was considered over-
conservative as the analyses were designed a priori to test a limited number of 
hypotheses and not all the tests were independent.[18]  We focused our interest on 
results with P-values <0.05 and considered consistency of the findings in our 
interpretation.  Stata® 11 (Stata Corp., College Station, TX) was used for all 
analyses. 
 
 
Results: 
Forty-one children were randomised (Figure 1)[19].  Twenty seven completed 32 
months, 3 were withdrawn (7%) and 11 had completed less than 32 months (26-31 
months) at study end.  Two children withdrew from the intervention group, after 22 
and 28 months, due to their families relocating out of region and one was withdrawn 
from the placebo group after 8 months because they were commenced on long-term 
nebulised antibiotics for clinical indications.  There were no withdrawals attributable 
to no longer wishing to take the study medication or due to dissatisfaction with any 
other element of the study protocol. Withdrawal rate did not differ between groups. At 
recruitment there were no significant between group differences in demographic or 
10 
 
clinical features (Table 1). Participants did not demonstrate a better than chance 
ability to guess their group allocation. 
 
The median number of occasions when a child was judged to require study 
medication was two in both groups.  Twelve children in the placebo group received 
at least one course of oral ciprofloxacin during the study period.  These individuals 
each received between one and eight courses.  Despite this, the total number of 
courses of ciprofloxacin prescribed according to the study protocol combined with 
those prescribed at the discretion of the clinical care team was significantly higher in 
the treatment group (p=0.0002).  Each child in the active treatment group received 
between one and eleven courses (Table 1).  
 
946 samples were collected during the study period of which 22 (2.3%) yielded 
positive cultures for P. aeruginosa.  Although there was an almost 50% reduction in 
the mean annual rate of P. aeruginosa isolates (0.17 versus 0.30), this difference 
was not significant (Table 2).  Nine of the 28 children in the active treatment group 
(32%) had at least one positive isolate of P. aeruginosa. For seven children this 
occurred on one occasion.  One child had two positive isolates and one child had 
positive isolates on three occasions.  Six out of 13 children receiving placebo (46%) 
had at least one positive isolate of P. aeruginosa, one child isolated P. aeruginosa 
on five occasions and five children had one positive isolate each.  A post hoc power 
calculation based on the annual rates of Pseudomonas isolates estimated that 80% 
power would require approximately 300 participants, therefore to account for a 
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withdrawal rate of approximately 7% at least  320 children would need to be 
recruited.  
 
The number of episodes of intravenous or nebulised antibiotic usage did not differ 
between active treatment and placebo groups and there were no between group 
differences in ELISA serology (Table 2).  Although the time to first P. aeruginosa 
isolate was shorter in the placebo group, this difference was not significant p=0.1, 
(Figure 2).  
 
There were no between group differences in the rate of isolation of any other 
microbial or fungal species (Table 3).  Median weight, height and FEV1 SD scores all 
improved between the beginning and end of the study period and there were no 
significant between group differences.  There were no cases of allergic 
bronchopulmonary aspergillosis and no reports of arthropathy or any other significant 
side effects in relation to the use of ciprofloxacin or placebo. 
 
Discussion: 
This study provides data about the safe use of two week courses of oral ciprofloxacin 
at times of acute respiratory infection in children 2 years of age or older who are not 
yet chronically infected with P. aeruginosa.  Within this pilot study there was no 
significant between group difference in the annual rate of P. aeruginosa isolates.  
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The study was designed as a pilot and unlikely to have sufficient power to detect a 
significant difference between groups for any outcome. It is possible, however, that 
the strong seasonal association found in epidemiological studies [12] between 
P.aeruginosa infection and respiratory virus infections might not reflect direct 
facilitation of P.aeruginosa infection at the time of viral infection.  Post-viral effects, 
such as mucus gland hypertrophy, might play a role in the seasonal associations 
reported.  The study design might therefore have failed to find a significant between 
group difference because the period of antibiotic cover was  insufficient.  
Nevertheless animal model data, demonstrate a facilitating effect upon Pseudomonal 
infection during early viral infection which supports investigation of this hypothesis in 
humans.[20]   
 
IAn important finding of relevance to proceeding to a definitive study was that the 
overall number of P. aeruginosa isolates in the control group was higher than 
anticipated,probably reflecting the intensity of microbial surveillance during the 
study.Despite this, only one child receiving placebo became chronically infected with 
P. aeruginosa and ELISA serology remained <1.00 (not indicative of chronic 
infection) in all study participants. Up to 11 courses of ciprofloxacin were prescribed 
to participants in the treatment arm of the study. An important clinical consideration 
is to weigh reduction of this relatively rare event against possible adverse drug 
effects or effects upon the microbiome of frequent broad spectrum oral antiobiotic 
administration.  
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One concern about the increased use of ciprofloxacin in young children is the 
emergence of resistant opportunistic airway pathogens.  Our results showed no 
between group difference in the annual rate of S. aureus isolates or any other known 
CF pathogens.  One child in the active intervention group who grew MRSA had 
grown this organism intermittently prior to study entry as had one of two children who 
grew atypical mycobacterial species.  Close surveillance for changes in the 
occurrence of other bacterial pathogens would be an important part of similar future 
studies.  
 
The study was subject to several limitations. The underlying rate of reported acute 
upper respiratory tract episodes was much lower than anticipated, and varied widely 
between patients [21].  In particular, very low rates of infective episodes were 
reported during late spring and summer months and for this reason the study was 
stopped earlier than had originally been planned and before all study participants 
had been followed up for 32 months.  It is possible that sub-clinical viral infections 
were not detected limiting the efficacy of the active treatment.  Equally, efficacy 
might have been improved by rapid diagnostic testing during viral infections to 
identify infective agents since the risk of Pseudomonal infection may reflect the 
causative virus, respiratory syncytial virus and influenza being particularly implicated 
in increasing the risk.[9, 22]  An unanticipated limitation was that the prescribing of 
ciprofloxacin as a treatment for respiratory symptoms during the study was higher 
than anticipated. Our current recommendations are for this to be used as a second 
line agent for two-week courses in children with ongoing cough, poorly responsive to 
first line therapies empirically treating Staphlococcus aureus and Haemophilus 
influenzae.  We believe this additional ciprofloxacin prescribing resulted from the CF 
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clinical team and participating families being aware of the information that formed the 
basis of the study hypothesis, resulting in a lower threshold for ciprofloxacin use in 
routine clinical practice.  This was highlighted and feedback to the clinical team by 
the trial’s independent data safety monitor.  
 
In general the clinical diagnosis of upper respiratory tract infection was felt to be 
accurate.  For example, parents were questioned about seasonality of symptoms 
and contact with other symptomatic individuals in order to distinguish allergic rhinitis 
from symptoms more suggestive of infective episodes.  Nevertheless viral testing 
would have both confirmed diagnosis and provided the added advantage of 
identifying the causative viral agent.  Many participants reporting episodes had 
accompanying cough at the time of initial presentation and the study protocol did not 
permit the use of study medication for these episodes, which were treated according 
to recommended guidelines [23].  A better study design might be to treat such 
episodes with study medication in addition to first line antibiotics.   
 
Cough swabs were the most commonly used microbial sample in this study with very 
few study participants able to expectorate sputum.  The sensitivity of these 
specimens probably underestimates the true rate of infection but this was partly 
offset by very frequent sampling at least every two months and at times of acute 
coughing for more than 2-3 days.  The negative ELISA assays provided further 
reassurances that the overall Pseudomonas bacterial load was low.  
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The optimal approach to treating initial isolates of P. aeruginosa in CF remains 
unclear and is the subject of ongoing clinical trials [24].  Whilst continuous prevention 
treatment has not been shown to be effective in preventing Pseudomonas infection, 
a more targeted use of anti-pseudomonal antibiotics at times of acute viral illness 
might be a more effective strategy.  On the basis of our data, a larger multi-centre 
clinical trial recruiting at least 320 patients would be needed to further explore this 
hypothesis.        
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Table 1:  Comparison of baseline data between intervention and placebo groups. 
 
 Intervention (n= 28) Placebo (n=13) P-value 
 
Demographics 
   
Age at recruitment, years (median 
(IQR)) 
6.61 (3.49, 11.38) 7.19 (2.74, 11.73) 0.90 
Gender (n (%))    
Male 15 (53.6) 6 (46.1) 0.74 
Female 13 (46.4) 7 (53.8)  
Centre (n (%))    
Southampton 18 (64.3) 7 (53.8) 0.73 
Poole/Winchester 10 (35.7) 6 (46.1)  
 
Clinical data 
   
Genotype DeltaF508:DeltaF508  
(n (%)) 
   
Yes 17 (60.7) 9 (69.2) 0.73 
No 11 (39.3) 4 (30.8)  
Newborn screened (n (%))    
Yes  4 (14.3) 4 (30.8) 0.24 
No 24 (85.7) 9 (69.2)  
Number of previous 
pseudomonas 
isolates (n (%)) 
0  12 (42.9) 7 (53.9) 0.72 
1 7 (25.0) 2 (15.4)  
2 4 (14.3) 2 (15.4)  
 3 1 (3.6) 0 (0.0)  
 4 1 (3.7) 1 (7.7)  
 5 2 (7.1) 1 (7.7)  
 6 1 (3.6) 0 (0.0) 
 
 
Weight SDS at recruitment (median 
(IQR)) 
-0.08 (-0.85, 0.36) -0.77 (-1.08, -
0.09) 
0.19 
Height SDS at recruitment (median 
(IQR)) 
-0.43 (-0.87, 0.21) -0.89 (-1.04, -
0.58) 
0.13 
ELISA at recruitment (median (IQR)) 0.49 (0.36, 0.61) 0.45 (0.31, 0.64) 0.64 
FEV1 at recruitment, percentage 
predicted (median (IQR)) 
97.8 (91.0, 109.0) 95.0 (84.0, 102.1) 0.14 
 
Study data 
   
Length in study, months (median 
(IQR)) 
32 (32, 32) 30.5 (27.5, 32) 0.08 
Number of viral infections treated 
under the study protocol per year in 
study (median (IQR)) 
0.75 (0, 1.5) 0.75 (0.38, 1.5) 0.58 
Number of courses of ciprofloxacin 
per year in study, total of those 
according to protocol and at clinical 
discretion (median (IQR)) 
1.88 (1.02, 2.26) 0.75 (0.38, 0.87) <0.001 
 
Binary outcomes were compared by Fishers exact test, categorical outcomes by a χ2 test for trend, 
and continuous variables using ranksum test.
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Table 2. Outcome data (1) – Between group comparisons of rate of pseudomonas isolates, treatment, ELISA serology, growth and lung 
function 
Outcome Active intervention Placebo Rank sum test  
P-value mean SD median IQR n mean SD median IQR n 
Episodes of pseudomonas/patient/year 0.17 0.29 0 0, 0.38 28 0.30 0.54 0 0, 0.38 13 0.41 
Episodes of intravenous antibiotics/patient/year 0.18 0.22 0 0, 0.38 28 0.25 0.42 0 0, 0.39 13 0.75 
Episodes of nebulised antibiotics/patient/year 0.82 0.94 1 0, 1 28 0.85 0.90 1 0, 1 13 0.84 
Change in ELISA serology 0.16 0.27 0.10 0.00, 0.30 16 0.10 0.37 0.1 -0.21, 0.42 4 0.90 
Change in weight SDS* 0.18 0.53 0.02 -0.28, 0.61 27 0.47 0.66 0.31 -0.12, 1.12 13 0.18 
Change in height SDS* 0.34 0.69 0.13 -0.10, 0.88 27 0.26 0.55 0.24 -0.02, 0.57 13 0.97 
Change in absolute FEV1 SDS* 0.51 0.49 0.43 0.12, 0.71 14 0.78 0.55 0.83 0.26, 0.86 7 0.25 
 
* All changes from study entry were in the direction of improvement for both study groups
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Table 3: Outcome data (2) – Between group comparisons of rate of isolation of other bacterial isolates 
Outcome Active intervention Placebo P-value 
mean SD median IQR n mean SD median IQR n 
Episodes of Staph aureus/patient/year 0.82 0.93 0.59 0-1.03 28 0.59 0.92 0.38 0-0.44 13 0.496 
Episodes of H. influenzae/patient/year 0.14 0.28 0 0-0.19 28 0.21 0.34 0 0-0.44 13 0.518 
Episodes of MRSA/patient/year 0.12 0.45 0 0-0 28 0 0 0 0-0 13 0.329 
Episodes of other bacterial isolates/patient/year 0.14 0.28 0 0-0.19 28 0.27 0.53 0 0-0 13 0.838 
Episodes of fungal isolates/patient/year* 0.66 2.0 0 0-0.38 28 0.58 1.86 0 0-0 13 0.625 
 
* Candida and aspergillus species. 
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Figure 1 Study participants flow diagram (Consort 2010) 
Figure 2 Kaplan-Meier survival estimate: Time to pseudomonas isolation 
